Synopsis: Josh Mandel-Brehm is the President and CEO of CAMP4 Therapeutics, a company pioneering mRNA amplification by using programmable ASO therapeutics to control gene expression. He joins host Rahul Chaturverdi to discuss the arc of his career and his interest in the intersection of business and science. They dive into the origins of CAMP4 and the inspiration behind the company’s name. He also talks about where CAMP4 is from a pipeline development perspective and how he approaches fundraising. Biography: Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics. Mr. Mandel-Brehm previously held roles as an entrepreneur partner with Polaris Partners and key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise and overseeing seminal investments to enter in gene therapy and the ophthalmology field. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit. Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related